Ovid Therapeutics‘s patent involves using allosteric modulators and/or gaboxadol to treat epileptic disorders. One claim specifies treating status epilepticus by administering ganaxolone via continuous intravenous infusion to maintain a specific plasma concentration. GlobalData’s report on Ovid Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights Ovid Therapeutics Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Ovid Therapeutics, Peptide pharmacophores was a key innovation area identified from patents. Ovid Therapeutics's grant share as of February 2024 was 20%. Grant share is based on the ratio of number of grants to total number of patents.

Treatment of status epilepticus with ganaxolone continuous intravenous infusion

Source: United States Patent and Trademark Office (USPTO). Credit: Ovid Therapeutics Inc

A recently granted patent (Publication Number: US11918563B1) discloses a method for treating status epilepticus in human patients using ganaxolone. The method involves administering an effective amount of ganaxolone as a continuous intravenous infusion to maintain a specific plasma concentration, with various concentration ranges specified in the claims. The treatment aims to provide improvement in symptoms for more than 8 hours, with some claims extending the duration to 12 or 24 hours. Additionally, the total amount of ganaxolone administered in a 24-hour period is limited to a range of 1 mg to 2500 mg, with specific upper limits outlined in the claims.

Furthermore, the patent details a method for treating status epilepticus by administering an intravenous infusion of ganaxolone within a specific dosage range, aiming to improve symptoms in patients in need of such treatment. The claims specify different dosage ranges for ganaxolone infusion, ranging from about 500 mg to 1050 mg per day, with variations in the dosage levels within this range. The method is designed to provide sustained improvement in symptoms for more than 8 hours, with specific dosage ranges outlined in the claims to achieve this therapeutic effect. Overall, the patent provides a detailed framework for utilizing ganaxolone in the treatment of status epilepticus, emphasizing specific dosage levels and infusion methods to optimize patient outcomes.

To know more about GlobalData’s detailed insights on Ovid Therapeutics, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies